First Eagle Investment Management LLC reduced its stake in shares of Vascular Biogenics Ltd. (NASDAQ:VBLT) by 26.5% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 655,574 shares of the biopharmaceutical company’s stock after selling 236,756 shares during the period. First Eagle Investment Management LLC owned 2.44% of Vascular Biogenics worth $2,917,000 at the end of the most recent reporting period.

Separately, KCG Holdings Inc. acquired a new stake in shares of Vascular Biogenics during the first quarter valued at $248,000. 12.99% of the stock is owned by institutional investors and hedge funds.

Shares of Vascular Biogenics Ltd. (NASDAQ VBLT) opened at 5.00 on Tuesday. The stock’s 50 day moving average price is $4.37 and its 200 day moving average price is $5.22. The firm’s market capitalization is $135.05 million. Vascular Biogenics Ltd. has a 52 week low of $3.90 and a 52 week high of $6.70.

Vascular Biogenics (NASDAQ:VBLT) last announced its quarterly earnings data on Monday, August 14th. The biopharmaceutical company reported ($0.18) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.19) by $0.01. On average, analysts predict that Vascular Biogenics Ltd. will post ($0.82) EPS for the current fiscal year.

WARNING: This news story was originally published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this news story on another site, it was illegally copied and reposted in violation of US & international copyright and trademark law. The correct version of this news story can be accessed at

Several analysts have recently weighed in on VBLT shares. Zacks Investment Research upgraded Vascular Biogenics from a “sell” rating to a “hold” rating in a research note on Tuesday, May 16th. ValuEngine downgraded Vascular Biogenics from a “hold” rating to a “sell” rating in a research note on Tuesday, June 6th. Finally, HC Wainwright set a $11.00 target price on Vascular Biogenics and gave the company a “buy” rating in a research note on Tuesday, August 15th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and four have issued a buy rating to the company. Vascular Biogenics currently has a consensus rating of “Buy” and an average price target of $12.90.

Vascular Biogenics Company Profile

Vascular Biogenics Ltd. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of treatments for cancer. The Company’s program is based on its Vascular Targeting System (VTS) platform technology, which utilizes genetically targeted therapy to destroy newly formed, or angiogenic, blood vessels.

Institutional Ownership by Quarter for Vascular Biogenics (NASDAQ:VBLT)

Receive News & Stock Ratings for Vascular Biogenics Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vascular Biogenics Ltd. and related stocks with our FREE daily email newsletter.